Finally, a catalytic light chain of botulism toxin E protease engineered to cleave SNAP23 suppresses in vivo tumorigenesis by KRAS-driven tumor cells, indicating that vesicular transporters may provide a therapeutic opportunity in KRAS-dependent malignancies. This evidence concerns the gene KRAS and neoplasm.